On November 3, 2022 Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, reported that an abstract on the effective cell dose and functional attributes of the company’s lead CD19 candidate, Azercabtagene Zapreleucel (azer-cel) was accepted for poster presentation at the 64th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition, being held December 10-13, 2022 in New Orleans, Louisiana (Press release, Precision Biosciences, NOV 3, 2022, View Source [SID1234622939]). Precision is currently evaluating azer-cel in a Phase 1/2a clinical trial of adult subjects with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) who relapsed following treatment with an autologous CAR T.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We look forward to seeing this data presented at the ASH (Free ASH Whitepaper) meeting and highlighting the differentiated product cellular attributes including product composition and cell doses that contribute to optimized efficacy and safety of azer-cel. This is the first analysis of an allogeneic CD19 CAR T product composition to demonstrate that strategies to maximize naïve cell phenotype may lead to improved safety and efficacy of an allogenic CAR T therapy," said Alan List, M.D., Chief Medical Officer of Precision BioSciences.
Poster Presentation Details:
Title: Effective Cell Dose and Functional Attributes of Azercabtagene Zapreleucel (azer-cel; PBCAR0191) Associate with Allogeneic CAR T-Cell Safety and Efficacy in Patients with Relapsed/Refractory B-Cell Lymphoma
First Author: Caron A. Jacobson, M.D., Dana Farber Cancer Institute
Poster Session: 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster I
Abstract #: 2005
Date/Time: Saturday, December 10, 2022, 5:30 PM – 7: 30 PM ET
Location: Ernest N. Morial Convention Center, Hall D